Alpha 2.0
Login Register
» Articles » PMID: 3181183

Modification by Nifedipine of 131I-meta-iodobenzylguanidine Kinetics in Malignant Phaeochromocytoma

Overview
Journal Eur J Nucl Med
Specialty Nuclear Medicine
Date 1988 Jan 1
PMID 3181183
Citations 11
Authors
G M Blake
V J Lewington
J S Fleming
M A Zivanovic
D M Ackery
Affiliations
Soon will be listed here.
Abstract

Following a case report that oral nifedipine can suppress the secretion of noradrenaline by phaeochromocytoma, we examined the effect of nifedipine on the tumour kinetics of tracer 131I-meta-iodobenzylguanidine (131I-mIBG) in five patients referred for mIBG radionuclide therapy for disseminated malignant phaeochromocytoma. In one subject a striking modification of mIBG kinetics was found that resulted in a doubling of the absorbed dose to tumour while the patient was taking nifedipine. At the same time, urinary excretion of noradrenaline was suppressed by a factor of three. The effect of nifedipine in this patient was confirmed when tracer studies were repeated nine months later. The changes in tumour kinetics were shown to be due to prolonged retention of mIBG rather than increased tumour blood flow or alteration of the curve of mIBG plasma concentration as a function of time.

Citing Articles

Imaging of Pheochromocytomas and Paragangliomas.

Timmers H, Taieb D, Pacak K, Lenders J Endocr Rev. 2024; 45(3):414-434.

PMID: 38206185 PMC: 11074798. DOI: 10.1210/endrev/bnae001.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taieb D, Hicks R, Hindie E, Guillet B, Avram A, Ghedini P Eur J Nucl Med Mol Imaging. 2019; 46(10):2112-2137.

PMID: 31254038 PMC: 7446938. DOI: 10.1007/s00259-019-04398-1.

Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Jacobson A, Travin M J Nucl Cardiol. 2015; 22(5):980-93.

PMID: 25975946 DOI: 10.1007/s12350-015-0170-z.

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taieb D, Timmers H, Hindie E, Guillet B, Neumann H, Walz M Eur J Nucl Med Mol Imaging. 2012; 39(12):1977-95.

PMID: 22926712 PMC: 4714772. DOI: 10.1007/s00259-012-2215-8.

131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.

Kara Gedik G, Hoefnagel C, Bais E, Olmos R Eur J Nucl Med Mol Imaging. 2007; 35(4):725-33.

PMID: 18071700 DOI: 10.1007/s00259-007-0652-6.

References
1.
Thomas S, Maxon H, KEREIAKES J . In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976; 03(04):253-5. DOI: 10.1118/1.594287. View
2.
Serfas D, Shoback D, Lorell B . Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade. Lancet. 1983; 2(8352):711-3. DOI: 10.1016/s0140-6736(83)92250-x. View
3.
McEwan A, Wyeth P, Ackery D . Radioiodinated iodobenzylguanidines for diagnosis and therapy. Int J Rad Appl Instrum A. 1986; 37(8):765-75. DOI: 10.1016/0883-2889(86)90271-6. View
4.
Tobes M, Jaques Jr S, Wieland D, Sisson J . Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985; 26(8):897-907. View
5.
Waller D, Renwick A, Gruchy B, George C . The first pass metabolism of nifedipine in man. Br J Clin Pharmacol. 1984; 18(6):951-4. PMC: 1463677. DOI: 10.1111/j.1365-2125.1984.tb02569.x. View